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Abstract 
The elderly constitute a growing world population group, with more than 200 million people 
over 60 years of age. This fact has increased the detection of chronic-degenerative diseases, as 
well as the prescription and consumption of medicines. The elderly are particularly susceptible 
to adverse drug events or interactions with other drugs due to their physiological changes, ge-
netic predisposition and environmental exposure. It becomes necessary to adapt the health 
systems with integral and multidisciplinary approaches suitable to this demographic change, as 
the knowledge about appropriate prescription, clinical pharmacology and medication use in the 
elderly has become essential. 
It has been shown that about two thirds of elderly patients receive inappropriate drug doses, 
and a substantial percentage of their hospital admissions are associated with potentially pre-
ventable toxic effects of drugs. To date, expert criteria, error detection tools and educational 
prescription plans have been developed by expert consensus for the safe use of drugs in the 
geriatric population. The objective of this study is a brief review of the principal physiological 
changes in an older adult, and summarize the contributions of the consensuses on prescription.
© 2014 Revista Medicina Universitaria. Facultad de Medicina UANL. Published by Elsevier México. All rights 
reserved. 
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Introduction
According to the World Health Organization (WHO), any in-
dividual who is more than 60 years old is considered el-
derly or an older person. This deinition applies for most 
industrialized countries and the UN.1 The number of el-
derly is increasing worldwide with over 200 million older 
people, and an increase of 30% is expected in the next few 
years.1
In Mexico, in 2010 the National Institute of Statistics and 
Geography (INEGI by its Spanish acronym) recorded over 
11 million elderly in its census,2 and according to the pro-
jections by the National Population Council, by the year 
2050 older people will represent 28% of the Mexican popula-
tion, with approximately 36 million people.3 Nowadays, the 
elderly population is growing twice as fast as the country’s 
population growth rate. 
The increase in life expectancy has an impact in terms of 
health, which is relected in a substantial increase in chron-
ic degenerative diseases, thus making the technological and 
economic development that this epidemiologic transition 
requires necessary, with a demand for multidisciplinary 
medical strategies. Prescription and consumption of medi-
cations has increased among the geriatric population, hence 
the presence of adverse pharmacological events. The objec-
tive of this document is to make a brief review of the main 
physiological changes of the elderly, as well as summarizing 
the contribution of consensuses about prescriptions in this 
population. 
Pharmacology in the elderly
The elderly population presents physiological and pharma-
cologic changes which make it especially susceptible to pre-
senting secondary or adverse events to medications, even 
with commonly used pharmaceutics.4,5 The need to know 
about prescriptions, clinic pharmacology and use of medica-
tion in the geriatric population becomes evident, in addition 
to preparing social, economic and health systems for cur-
rent and future population demographic changes.6-8 It is es-
timated that people over 65 consume 25-50% of all 
prescribed pharmaceutics, and are responsible for 70% of 
the total pharmaceutical expenditure.9 Different studies 
have calculated that two thirds of geriatric patients receive 
an inappropriate dosage of medication, especially those 
with renal elimination.10-12 Moreover, the harmful effects of 
the pharmaceutics may have safety consequences and eco-
nomically affect the health system.13
Approximately 30% of hospital admissions of older pa-
tients is linked to the toxic effects of pharmaceutics. The 
related adverse effects of pharmaceutics have been associ-
ated with preventable problems, like depression, constipa-
tion, falls, immobility, confusion and hip injuries.13
In a study conducted in patients who live in retirement 
homes, it was proved that approximately two thirds of 
residents had an ADR in a period of four years and out of 
them 1 in 7 required hospitalization.14 In the US in 2012 
problems related to medications caused 106 000 deaths 
with a cost of 85 billion dollars. Other authors have calcu-
lated the ADR-related expenditure to be $76.6 billion in 
outpatient care, $20 billion in hospitals and $4 billion in 
nursing homes.13,15
Physical changes in the elderly
Physiologically, the elderly is in a state characterized by a 
reduction in functional reserves and their ability to 
adapt,6,16-18 which suggests a different response to that of a 
young patient when dealing with a disease or the adminis-
tration of certain medication. Proper knowledge of the 
changes in pharmacokinetics and pharmacodynamics in the 
elderly is necessary for a correct prescription, which mini-
mizes or avoids adverse effects of medications.6,18-20
Variability in response to pharmacological intervention is 
conditioned by genetic factors, age, diseases, interactions 
and prescription compliance, which results in alterations in 
the pharmacokinetics and pharmacodynamics proiles, in 
addition to the frequent atypical presentations of diseases 
and the administration of multiple medications.21,22
Pharmacokinetics
Pharmacokinetics determine the relationship between a 
medication administration and the concentration which it 
reaches in the body with time (in relationship with the dos-
age, presentation, frequency and form of administration), 
and despite the fact that many changes of these parameters 
have been described, inter-individual variability is the 
rule.6,18,19
Bioavailability refers to the proportion of the medication 
that reaches circulation, and it is a function of the form of 
administration, the chemical properties of the medication 
and the absorption and amount of dosage which is elimi-
nated through the hepatic metabolism of the irst step be-
fore reaching circulation.6,17 Bioavailability is affected by 
age, because absorption becomes slower, increasing the 
necessary time to reach maximum concentration in plasma. 
Some medications require an acid environment for its ab-
sorption, like ketoconazole, ampicillin or iron, and may 
have a decline of their bioavailability from 5 to 10%, as a 
result of hypochlorhydria secondary to atrophic gastritis or 
treatment with H2 antagonists and proton-bomb inhibi-
tors.17-19 In the elderly, the hepatic metabolism of the irst 
step is diminished, and oral medication bioavailability which 
goes through this process is greater.17,18
Distribution volume depends on the plasma’s union to pro-
tein, on water and lipid proportion and on tissue perfusion. 
The latter may decrease with age, causing a slower distribu-
tion, and a reduction of the dosage load with most medica-
tions should be considered.17,18 Concerning water and lipids 
proportion, body fat in the elderly is considered to increase 
between 20 and 40% and corporal water decreases by 10 to 
15%, leading to an increase in concentration of water-solu-
ble medications and a slower elimination of fat-soluble 
medications.18-21
Some medications which present a lower distribution vol-
ume in the elderly are digoxin, cimetidine, gentamicin, 
phenytoin and theophylline, among others, and this trans-
lates to high plasmatic levels of the medications.18
The most important elimination mechanisms are hepatic 
and renal. Hepatic metabolism in older people has a sub-
stantial decrease in its activity and there are also changes in 
the gastrointestinal system, like a decrease in gastric acid 
secretion and intestinal motility.6,19 This decrease in elimi-
nation rate prolongs medications’ half-lives and carries with 
it the need to increase administration intervals.6,18 This oc-
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curs with medications like acetaminophen, amitriptyline, 
barbiturates, ibuprofen, lidocaine, prazosin, propranolol, 
salicilates and warfarin, among others.18
Pharmacodynamics
Pharmacodynamics describes the effects of medications in 
tissue (what medications cause in the body).6-18 Although it 
can be altered by age, these changes have not been thor-
oughly studied. Almost every action of the medications are 
mediated by a interaction of medication molecules with tis-
sue receptors, and these can be altered by hormones, neu-
rotransmitters and transportation systems, among others, 
and the central nervous and cardiovascular systems play a 
very important role.6
Pharmacogenetics
Genetic variation is one of the causes of versatility in re-
sponses to medications and is estimated to contribute be-
tween 20 and up to 95%, even though the genetic expression 
can also be related to age and environmental factors.6 The 
aging process itself and the presentation of diseases have 
polygenic causes, thus the response to many medications 
can also be altered by polymorphisms in genes that may not 
be responsible for the pharmacokinetic or are not its direct 
target.6 In table 1 there is a summary of the main physiolog-
ical changes linked to age.
Adverse effects of the use of medications 
in geriatrics
Prescription errors in the elderly population are generally 
related to pharmacological changes, inadequate orientation 
about dosage modiication, and lack of recommendations or 
guides about safety of some medications in the geriatric 
population.21,22
Sometimes, randomized and controlled studies do not in-
clude patients over 65 years, consequently the results on 
the safety of some medications cannot be generalized to 
this population. Adverse effects of medications include ad-
verse reactions and prescription errors. An adverse medica-
tion reaction (AMR) is defined as any undesired sign or 
symptom which appears after medication administration at 
therapeutic doses. A severe or extremely severe AMR is one 
which requires hospitalization or causes irreversible damage 
including death.1,6,18 Adverse reactions are classiied based 
on their relation with a medication in five groups (A-E). 
Type A is linked to the medication’s pharmacologic action, 
predictable or dosage-associated (pharmacokinetic chang-
es, medication-medication, medication-food or medication-
disease interactions), and represent most of the adverse 
effects. In group B there is no relation with pharmacologic 
actions and are independent of dosage, these are less fre-
quent but more severe (allergic reactions, cytotoxic, idio-
syncratic, etc.), and are unpredictable.22,23 The reactions of 
group C are related to prolonged and continuous use of a 
medication, such as dependency reactions or tachyphylaxis. 
Group D refers to late or long-term reactions like teratoge-
nicity, and carcinogesis and group E is produced when a 
medication is suspended (“rebound effect”).
However, there are many classification systems. Mallet 
et al suggest a simple approach to the problem, and summa-
rizes it in three categories, which are adverse reactions by 
pharmacologic interactions; patients who consume multiple 
medications and/or have multiple diseases (nine or more 
medications and ive or more comorbidities); and the “pre-
scription cascade” phenomenon, where the adverse effect of 
a medication leads to the prescription of another agent which 
at the same time causes a new secondary effect which would 
add a new medication.23-25 Most adverse reactions to medica-
tions in hospitalized elderly are type A and therefore repre-
sent predictable reactions and are potentially preventable.26,27
The medications that relate the most to adverse reactions 
and events are medications used to treat cardiovascular dis-
eases, followed by rheumatologic and endocrinological 
medications, and this corresponds with the frequency and 
morbidity of these diseases in Mexico.27
Polypharmacy
The use of concomitant medications is justiied in the treat-
ment of multiple chronic diseases. Polypharmacy is a term 
which describes patients who receive multiple medications, 
and in the elderly, this represents the rule rather than the 
exception.16,17
According to data from population studies in the United 
States, 90% of the elderly consume at least a weekly medi-
cation, over 55% of women and 44% of men of advanced age 
consume ive medications or more, and 40% of residents in 
nursing homes consume over eight weekly medications.4,5,16
With this practice the risk of AMR increases drastically, 
because on many occasions, there are duplicates of the 
same kind of medication, and the adverse effects are not 
identiied, leading to a prescription cascade.23-25,28
Adverse reactions may be dificult to detect in elderly pa-
tients because they frequently have atypical presentations, 
like lethargy, confusion, falls, constipation and depression. 
Table 1 Principal physiological changes in the elderly
Absorption Decrease of absorption surface, alteration in 
gastrointestinal motility, decrease of splenic low
Distribution Decrease of total body water and muscular mass, 
decrease of albumin, altered protein binding
Greater concentration of hydrosoluble 
pharmaceutics, increase in elimination of 
liposoluble pharmaceutics
Metabolism Reduction of hepatic mass and low, decrease of type I 
metabolism
Decrease of irst step metabolism
Elimination Decrease of renal low, GFR and secretory function Decrease in elimination of medications
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Nursing homes residents are the most vulnerable of this 
group.28
An appropriate use of medications 
in geriatrics? 
With the purpose of minimizing the problems that emerge 
as a consequence of inappropriate prescription of medica-
tions in the elderly, consensus criteria have been developed 
in order to improve safety among this population. 
Beers criteria
Beers et al,28 in 1999, supported by a group of experts in 
geriatrics, geriatric pharmacology, psychopharmacology and 
pharmacoepidemiology, in addition to the revision of scien-
tiic literature, developed a consensus of medications used 
in the elderly and their frequent adverse effects. Criterion 
were developed which have been widely used to describe 
treatment patterns and educate and inform clinical doctors. 
A revision of these criteria was made in 199729 and later in 
200330 to reevaluate new products, to reassess the severity 
assigned to each medication and to identify new situations 
or major considerations. The application of these criteria 
have allowed an improvement of pharmacological therapy 
safety, since it identiies risk factors associated with pre-
scription and suggests safety improvement programs. 
Beers’ criteria grouped medications into two groups; med-
ications which should be avoided by the elderly because of 
their inefficacy or representation of an unnecessary risk, 
having other alternatives (table 2), and those medications 
which should not be used in the elderly even when they 
meet speciic medical requirements (table 3). Moreover it 
stresses the importance of identifying prescription cascade.13
Table 3 Medications speciically inappropiate for the elderly by clinical diagnosis
Diagnosis Medication Effect
Cardiac failure Disopyramide Negative inotropic effect
Urinary obstruction with overlow Anticholinergics and antihistamines, 
muscle relaxants
Urinary retention
Urinary incontinence due to stress Alpha blockers, anticholinergics, 
tricyclic antidepressants, doxepin, 
benzodiazepines
May cause polyuria and worsen urinary 
incontinence
Arrhythmias Tricyclic antidepressants Pro-arrhythmic effects
Parkinson’s disease Metoclopramide Cholinergic, antidopaminergic effects
Depression Benzodiazepines Exacerbates depression
Adapted from Fick et al.13
Table 2 Medications speciically inappropriate for the elderly
Indomethacin Associated with CNS effects
Muscle relaxants and antispasmodics (methocarbamol, 
cyclobenzaprine, oxybutynin)
Poorly tolerated, cause sedation and weakness
Amitriptyline/doxepin Important anticholinergic and sedative action
Long-acting benzodiazepines Have long half-life in adults, increases risk of falls and 
fractures
Digoxin >0.125 mg/day Increased toxicity risk
Methyldopa May cause bradycardia and exacerbate depression
Chlorpropamide Long half-life in adults, prolonged hypoglycemia
Gastrointestinal antispasmodics Anticholinergic effects
Anticholinergics and antihistamines Important anticholinergic action, confusion, sedation
Barbiturates (except phenobarbital) Addictive, sedative effects
Meperidine Confusion
Ketorolac, NSAIDS Gastric bleeding, kidney failure
Amiodarone Electrocardiographic abnormalities, torsade de pointes
Nitrofurantoin Kidney failure 
Nifedipine (short acting) Hypotension and constipation
CNS: central nervous system; NSAIDS: non-steroidal anti-inlammatory drugs.
Adapted from Fick et al.1
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Medications mostly implicated in adverse events are 
cardiovascular, antibiotics, diuretics, anticoagulants, hy-
poglycemiants, steroids, opiates, anticholinergics, benzo-
diazepines and non-steroidal anti-inlammatory, among 
others.
While Beers’ criteria is very useful, there are some limita-
tions in their use. Some medications listed as inappropriate, 
may have acceptable applications; likewise, there are med-
ications which are not included and may confer risk with 
their use.7,31,32
The InterRAI Corporation is a network of researchers and 
clinics from 30 different countries around the world, and it 
has developed and standardized instruments for geriatric 
care currently being used in many countries. These instru-
ments provide valid scales in geriatric patients, important 
in clinical practice, which may have a positive effect on in-
dividual care and treatment.7,33
In 2009, Hanlon et al conducted a consensus in order to 
establish guidelines for the use of oral medications with re-
nal elimination used in the elderly. The obtained results 
were in the form of two recommendations, medications 
which should be avoided in patients with a renal function of 
<30 mL/min like chlorpropamide, colchicine, cotrimoxa-
zole, glyburide, meperidine, nitrofurantoin, probenecid, 
propoxyphene, spironolactone and triamterene; and those 
which require dosage reduction or a more ample adminis-
tration interval, like acyclovir, amantadine, ciproloxacin, 
gabapentin, memantine, ranitidine, rimantadine and vala-
cyclovir. Frequently used medications which require renal 
adjustment can be found in table 4. 
Two identiication tools to identify mistakes in prescrip-
tions for the elderly were developed with the use of the Eng-
lish acronyms STOPP (screening tool of older persons’ 
prescription) and START (screening tool to alert to right treat-
ment); identifying those medications which should be avoid-
ed, as well as those appropriate in the treatment of the 
elderly. The most commonly used medications are mentioned 
in tables 5 and 6.34 These studies proved that the potential 
omission of adequate medications in the elderly is as preva-
lent as the inclusion of inappropriate medications which 
should be avoided.5,34 A multidisciplinary team allows for a 
better quality in the attention of the elderly, and adequate 
prescriptions and an optimal control with a decrease of AMR.
Education for prescriptions and general 
standards
The challenge in prescribing medicine 
to the elderly
The elderly have approximately 3 times more prescriptions 
than younger people. While the metabolism characteristics 
of geriatric patients which affect medication pharmacology 
are not modiiable, the choice of medication, length of the 
treatment and dosages are decisions which depend on the 
doctor, and are factors which can be optimized with the 
right knowledge and proper training in the treatment of ge-
riatric patients.
Every new medication must be evaluated in the following 
contexts: pharmacokinetic, pharmacodynamics and changes 
Table 4 Commonly used medications that require renal adjustment
Medications Creatinine clearance (mg/ml) Recommended dose
Acyclovir (Herpes zoster) 10-29 800 mg/8 h
<10 800 mg/12 h
Ciproloxacin <30 500 mg/24 h
Colchicine <10 Do not use
Gabapentin 30-59 600 mg/12 h
15-29 300 mg/12 h
<15 300 mg/24 h
Nitrofurantoin <60 Do not use
Probenecid <50 Do not use
Ranitidine <50 150 mg/24 h
Spironolactone <30 Do not use
Allopurinol 10-50 200 mg/24 h
<10 100 mg/24 h
Cetirizine 10-30 5 mg/24 h
<10 Do not use
Cimetidine <50 Do not use
Fexofenadine <80 60 mg/24 h
Hydrochlorothiazide <30 Do not use
Metformin <60 Do not use
Metoclopramide <40 Do not use
Adapted from Hanlon et al.10
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related to age regarding body composition and physiology.28 
While on occasion there are differences between geriatric 
guidelines and clinical practices from country to country, 
and the prescription is strongly influenced by feedback 
strategies and national forms, it is important to harmonize 
clinical and political recommendations as well as effective 
measures applied to our population in order to improve 
medical prescription.
Planning of an integral systemic approach to the elderly 
and teaching strategies for continuous medical education, 
Table 5 Medications inappropriate for patients over 65 years, STOPP (Screening Tool of Older Persons’ Prescription)
Cardiovascular system Digoxin at a dosage >125 mg/day with 
creatinine clearance <50 mL/min
Increases toxicity
Loop diuretics as a irst-line monotherapy 
for HAS
Better, safer, and more effective options
Loop diuretics for leg edema without heart 
failure
No evidence of eficacy
Thiazide diuretics with a history of gout May exacerbate gout
Nonselective beta blocker with COPD May cause bronchospasm
Calcium channel blockers with constipation May exacerbate constipation
Verapamil or diltiazem with congestive 
cardiac failure class III o IV (NYHA)
May worsen cardiac failure
Aspirin or warfarin without gastric 
protection agents
Risk of gastric bleeding
Aspirin without a history of peripheral 
arterial, coronary or cerebral disease
Not indicated
Central nervous system Tricyclic anti-depressants with:
  Dementia Risk of worsening cognitive state
  Glaucoma Exacerbates glaucoma
  Abnormalities of cardiac conduction Pro-arrhythmic effects
  History of urinary retention Risk of urinary retention
Neuroleptics >1 month con Parkinson’s Worsens extrapyramidal symptoms
Long-term neuroleptics or benzodiazepines Likelihood of confusion, prolonged 
sedation, extrapyramidal effects, falls
Anticholinergics to treat extrapyramidal 
side effects secondary to other medications
Risk of anticholinergic toxicity
Prolonged use (>1 week) of irst-generation 
antihistamines
Risk of sedation and anticholinergic 
effects
Gastrointestinal system Loperamide, diphenoxylate, codeine 
phosphate for the treatment of diarrhea 
with an unknown cause
Risk of constipation, diarrhea overload, 
or toxic megacolon
Respiratory system Antispasmodic anticholinergics with chronic 
constipation 
Exacerbates constipation
Theophylline monotherapy for EPOC There are safer options
Musculoskeletal system Nebulized ipratropium con glaucoma May exacerbate glaucoma
NSAID with a peptic ulcer Bleeding
NSAID and HAS or cardiac failure May exacerbate HAS
Urogenital system NSAID or colchicine for gout (when there is 
no contraindication to allopurinol)
Prophylactic allopurinol as a choice in 
patients with gout
Endocrine system Antimuscarinics with dementia, glaucoma May exacerbate constipation or 
prostatism
Glibenclamide or chlorpromazine in type-2 
DM
Risk of prolonged hypoglycemia
Estrogens with a history of breast cancer or 
thromboembolism
Risk of recurrence
Estrogen without progesterone in 
nulliparous patients
Risk of endometrial cancer
COPD: chronic obstructive pulmonary desease; NSAID: non-steroidal anti-inlammatory drug; NYHA: New York Heart Association.
Adapted from O’Mahony et al.34
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represent an essential component of a quality medical edu-
cation.35-36 Some important points to consider, with the pur-
pose of improving the quality of prescriptions in the geriatric 
population, are: to conduct an integral assessment of pa-
tients, in the medical, functional, mental and social as-
pects; to use medications of proven eficacy, known toxicity 
and with experience of use in the geriatric population, to 
periodically review medications prescribed by different 
doctors, including dosage and length; to avoid unnecessary 
medication; periodical monitoring and evaluation of thera-
peutic objectives and whether or not these are properly be-
ing met; prescribe medications with fewer adverse reactions 
and interactions; choose medications with easily recogniz-
able presentations and administration intervals which allow 
for adequate compliance; search for the minimum effective 
dosage and increase progressively if necessary, as well as 
educate the patient and personnel responsible for their care 
on the proper administration, which avoids self-medica-
tion.8-9, 24, 35,36
Conclusions 
The elderly present physiological changes which affect the 
pharmacology of the medications used. Pharmacological 
studies cannot always extrapolate a medicine’s effect on 
the elderly, thus the most important challenge is to achieve 
optimal pharmacotherapy individualization.
The application of consensus criteria during prescription 
helps the clinic in the decision-making process and func-
tions as a tool to minimize problems associated with the use 
of medications. Prescription must be based on general stan-
dards or principles of the use of medications in the elderly, 
whose main objective is to decrease the use of multiple 
medications and increase safety and treatment adhesion.
Table 6 Medications appropriate for patients over 65 years. START (Screening Tool to Alert to Right Treatment)
 Medications
Cardiovascular system Warfarin in atrial ibrillation
Aspirin or clopidogrel with a history of coronary, cerebral or peripheral atherosclerosis
Antihypertensive therapy if blood pressure >160 mmHg
Beta-blockers in chronic stable angina
NSAIDs in heart failure or after acute myocardial infarction
Respiratory system Anticholinergic agonist β2 inhaled for light to moderate asthma
Supplementary oxygen in case of respiratory failure type-1 or 2
Gastrointestinal system Proton pump inhibitors with GERD history
Fiber supplements for symptomatic constipation
Musculoskeletal system Disease-modifying drugs with severe rheumatoid arthritis 
Bisphosphonate in patients with long-term steroid therapy
Calcium and vitamin D supplements in patients with osteoporosis
Endocrine system Metformin with type-2 diabetes mellitus and metabolic syndrome
NSAIDs in diabetes mellitus with nephropathy
Antiplatelets or statins in diabetic patients with major cardiovascular risk factors
NSAID: non-steroidal anti-inlammatory drug.
Adapted from O’Mahony et al.34
Physicians who attend the elderly should integrate their 
individual clinical experience with the best external evi-
dence and comprehensible information in prognosis, limita-
tions, preferences, family support and cost of treatment. A 
multidisciplinary approach and assistance coordination are 
indispensable in order to optimize this process.
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